Comparative Pharmacology
Head-to-head clinical analysis: BUTOCONAZOLE NITRATE versus SELENIUM SULFIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTOCONAZOLE NITRATE versus SELENIUM SULFIDE.
BUTOCONAZOLE NITRATE vs SELENIUM SULFIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Selenium sulfide is an antifungal and cytostatic agent. It reduces sebum production and inhibits the growth of Malassezia species by interfering with fungal lipid metabolism and cell wall synthesis. The exact molecular mechanism is not fully elucidated.
Intravaginal administration: 100 mg (one applicatorful of 2% cream) once daily for 3 days; or 100 mg (one suppository) once daily for 3 days; or 5 g (one applicatorful of 4% cream) as a single dose.
Topical: 2.5% lotion or shampoo applied to affected area once daily for 7 days; 1% shampoo used once or twice weekly for maintenance.
None Documented
None Documented
Terminal half-life is approximately 21–24 hours, supporting once-daily or twice-weekly dosing for vaginal candidiasis.
Not established; due to negligible systemic absorption, a terminal half-life is not clinically relevant. If absorbed, selenium has a long biological half-life of approximately 65–115 days due to incorporation into selenoproteins.
Primarily hepatic metabolism with <5% excreted unchanged in urine; fecal elimination accounts for ~30% of metabolites.
Selenium sulfide is minimally absorbed after topical application. The small absorbed fraction is excreted renally as selenite or selenate, with fecal excretion of unabsorbed drug accounting for >90% of the dose.
Category A/B
Category A/B
Antifungal
Antifungal / Antiseborrheic